240 related articles for article (PubMed ID: 7632963)
21. Frequent hypermethylation of p16 and p15 genes in multiple myeloma.
Ng MH; Chung YF; Lo KW; Wickham NW; Lee JC; Huang DP
Blood; 1997 Apr; 89(7):2500-6. PubMed ID: 9116295
[TBL] [Abstract][Full Text] [Related]
22. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma.
Koduru PR; Zariwala M; Soni M; Gong JZ; Xiong Y; Broome JD
Blood; 1995 Oct; 86(8):2900-5. PubMed ID: 7579381
[TBL] [Abstract][Full Text] [Related]
23. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias.
Hebert J; Cayuela JM; Berkeley J; Sigaux F
Blood; 1994 Dec; 84(12):4038-44. PubMed ID: 7994022
[TBL] [Abstract][Full Text] [Related]
24. Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors.
Packenham JP; Taylor JA; Anna CH; White CM; Devereux TR
Mol Carcinog; 1995 Nov; 14(3):147-51. PubMed ID: 7576106
[TBL] [Abstract][Full Text] [Related]
25. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias.
Hayette S; Thomas X; Bertrand Y; Tigaud I; Callanan M; Thiebaut A; Charrin C; Archimbaud E; Magaud JP; Rimokh R
Leukemia; 1997 Oct; 11(10):1696-9. PubMed ID: 9324291
[TBL] [Abstract][Full Text] [Related]
26. Deletion mapping indicates that MTS1 is the target of frequent deletions at chromosome 9p21 in paediatric acute lymphoblastic leukaemias.
Guidal-Giroux C; Gérard B; Cavé H; Duval M; Rohrlich P; Elion J; Vilmer E; Grandchamp B
Br J Haematol; 1996 Feb; 92(2):410-9. PubMed ID: 8603008
[TBL] [Abstract][Full Text] [Related]
27. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
28. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features.
Fizzotti M; Cimino G; Pisegna S; Alimena G; Quartarone C; Mandelli F; Pelicci PG; Lo Coco F
Blood; 1995 May; 85(10):2685-90. PubMed ID: 7742527
[TBL] [Abstract][Full Text] [Related]
29. Primary malignant lymphoma of the brain: demonstration of frequent p16 and p15 gene deletions.
Kumanishi T; Zhang S; Ichikawa T; Endo S; Washiyama K
Jpn J Cancer Res; 1996 Jul; 87(7):691-5. PubMed ID: 8698617
[TBL] [Abstract][Full Text] [Related]
30. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.
Li YJ; Hoang-Xuan K; Delattre JY; Poisson M; Thomas G; Hamelin R
Oncogene; 1995 Aug; 11(3):597-600. PubMed ID: 7630644
[TBL] [Abstract][Full Text] [Related]
31. Mutational analysis of the p15 and p16 genes in acute leukaemias.
Sill H; Aguiar RC; Schmidt H; Hochhaus A; Goldman JM; Cross NC
Br J Haematol; 1996 Mar; 92(3):681-3. PubMed ID: 8616035
[TBL] [Abstract][Full Text] [Related]
32. Infrequent mutations and no methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan.
Lin YW; Chen CH; Huang GT; Lee PH; Wang JT; Chen DS; Lu FJ; Sheu JC
Eur J Cancer; 1998 Oct; 34(11):1789-95. PubMed ID: 9893670
[TBL] [Abstract][Full Text] [Related]
33. Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias.
Nakamaki T; Kawamata N; Schwaller J; Tobler A; Fey M; Pakkala S; Lee YY; Kim BK; Fukuchi K; Tsuruoka N
Br J Haematol; 1995 Sep; 91(1):139-49. PubMed ID: 7577621
[TBL] [Abstract][Full Text] [Related]
34. p16INK4A and p15INK4B gene deletions in primary leukemias.
Haidar MA; Cao XB; Manshouri T; Chan LL; Glassman A; Kantarjian HM; Keating MJ; Beran MS; Albitar M
Blood; 1995 Jul; 86(1):311-5. PubMed ID: 7795238
[TBL] [Abstract][Full Text] [Related]
35. Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non-small cell lung cancers.
Kawamata N; Miller CW; Koeffler HP
Mol Carcinog; 1995 Dec; 14(4):263-8. PubMed ID: 8519415
[TBL] [Abstract][Full Text] [Related]
36. Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers.
Shimizu T; Sekiya T
Int J Cancer; 1995 Nov; 63(5):616-20. PubMed ID: 7591275
[TBL] [Abstract][Full Text] [Related]
37. Alterations of p16 and p15 genes in acute leukemia with MLL gene rearrangements and their correlation with clinical features.
Ohnishi H; Guo SX; Ida K; Taki T; Naritaka S; Bessho F; Yanagisawa M; Hanada R; Eguchi M; Kamada N; Kita K; Yamamori S; Hayashi Y
Leukemia; 1997 Dec; 11(12):2120-4. PubMed ID: 9447829
[TBL] [Abstract][Full Text] [Related]
38. Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias.
Ogawa S; Hirano N; Sato N; Takahashi T; Hangaishi A; Tanaka K; Kurokawa M; Tanaka T; Mitani K; Yazaki Y
Blood; 1994 Oct; 84(8):2431-5. PubMed ID: 7919362
[TBL] [Abstract][Full Text] [Related]
39. Deletions and rearrangement of CDKN2 in lymphoid malignancy.
Stranks G; Height SE; Mitchell P; Jadayel D; Yuille MA; De Lord C; Clutterbuck RD; Treleaven JG; Powles RL; Nacheva E
Blood; 1995 Feb; 85(4):893-901. PubMed ID: 7849311
[TBL] [Abstract][Full Text] [Related]
40. Incidence and clinical significance of CDKN2/MTS1/P16ink4A and MTS2/P15ink4B gene deletions in childhood acute lymphoblastic leukemia.
Zhou M; Gu L; Yeager AM; Findley HW
Pediatr Hematol Oncol; 1997; 14(2):141-50. PubMed ID: 9089742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
